(Q35107741)

6 August 2017

1 reference

title

The triptan formulations : how to match patients and products (English)

1 reference

6 August 2017

3

Marcelo E Bigal

1 reference

6 August 2017

2

Stewart J Tepper

1 reference

6 August 2017

Alan M Rapoport

1

1 reference

6 August 2017

Fred D Sheftell

series ordinal

4

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

431-447

1 reference

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

6 August 2017

cites work

1 reference

12 December 2020

Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients

1 reference

12 December 2020

Triptans and coronary spasm

1 reference

12 December 2020

Sumatriptan in clinical practice: a 2-year review of 453 migraine patients

1 reference

12 December 2020

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

1 reference

12 December 2020

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

1 reference

12 December 2020

Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.

1 reference

12 December 2020

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

1 reference

12 December 2020

Comparison of rizatriptan and other triptans on stringent measures of efficacy

1 reference

12 December 2020

Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites

1 reference

12 December 2020

The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group

1 reference

12 December 2020

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

1 reference

12 December 2020

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

1 reference

12 December 2020

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

1 reference

12 December 2020

A long-term study to maximise migraine relief with zolmitriptan

1 reference

12 December 2020

Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans

1 reference

12 December 2020

A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group

1 reference

12 December 2020

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

1 reference

12 December 2020

Zolmitriptan versus sumatriptan comparison trial

1 reference

12 December 2020

Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan

1 reference

12 December 2020

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

1 reference

12 December 2020

Treatment of Acute Migraine With Subcutaneous Sumatriptan

1 reference

12 December 2020

Triptans are all different

1 reference

12 December 2020

Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine

1 reference

12 December 2020

Pharmacology and potential mechanisms of action of rizatriptan

1 reference

12 December 2020

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

12 December 2020

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

1 reference

12 December 2020

Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group

1 reference

12 December 2020

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

12 December 2020

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

1 reference

12 December 2020

The pharmacology of the novel 5-HT1-like receptor agonist, GR43175.

1 reference

12 December 2020

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

1 reference

12 December 2020

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study

1 reference

12 December 2020

Simultaneous measurement of zolmitriptan and its major metabolites N-desmethylzolmitriptan and zolmitriptan N-oxide in human plasma by high-performance liquid chromatography with coulometric detection

1 reference

12 December 2020

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

1 reference

12 December 2020

Safety, Tolerability, and Pharmacokinetics of Sumatriptan Suppositories Following Single and Multiple doses in Healthy Volunteers

1 reference

12 December 2020

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

12 December 2020

Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths

1 reference

12 December 2020

Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group

1 reference

12 December 2020

Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study

1 reference

12 December 2020

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society

1 reference

12 December 2020

Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis

1 reference

12 December 2020

A quantitative analysis of the intranasal delivery of topical nasal drugs to the middle meatus: spray versus drop administration.

1 reference

12 December 2020

1 reference

12 December 2020

Sumatriptan suppositories for the acute treatment of migraine. S2B351 Study Group.

1 reference

12 December 2020

Tolerability and efficacy of almotriptan in the long-term treatment of migraine

1 reference

12 December 2020

10.2165/00023210-200317060-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

1021634222

0 references

1 reference